Replies to post #117291 on Biotech Values

[bladerunner1717]

jq1234,

Why did Roche change to a different combination?


Bladerunner

[genisi]

However, accelerated approval landscape in oncology has changed a little bit especially with Avastin situation in MBC

Iressa in NSCLC is another case in point. Getting a new cancer drug approved based on data from a single arm trial is definitely getting harder especially with no survival data. The drug needs to show a very very high response rate or to aim at an unmet medical need.